Haleon To Sell ChapStick Lip Balm For $510M

151
SHARE
Haleon To Sell ChapStick Lip Balm For $510M

In a seismic business maneuver, Haleon PLC declared on Thursday its landmark decision to offload the iconic ChapStick lip balm brand to Suave, the U.S. titan renowned for hair and body care, in a deal worth a staggering $510 million. This strategic move is part of Haleon’s ambitious plan to streamline its operations and alleviate its debt burden.

Enter Email to View Articles

Loading...

Suave Brands Co. Snags ChapStick in $510 Million Cash Splash

Suave Brands Co., operating independently under the umbrella of investment firm Yellow Wood Partners, is set to splash approximately $430 million in cash to acquire the beloved ChapStick. Adding an extra layer of complexity to the deal, Haleon will also secure a minority interest in Suave, evaluated at around $80 million, as disclosed on the U.K. firm’s official website.

Haleon To Sell ChapStick Lip Balm For $510M : Awaiting Regulatory Nod

The proposed acquisition, shrouded in anticipation, is contingent upon the fulfillment of undisclosed closing and regulatory conditions. The finalization of this groundbreaking deal is projected to unfold between the months of April and June, injecting an air of mystery and excitement into the financial landscape.

 Yellow Wood Partners Navigates the Legal Maze

Leading the charge in navigating the legal intricacies of this monumental transaction is Fried Frank Harris Shriver & Jacobson LLP, serving as the legal counsel for Yellow Wood Partners. The legal representation for Haleon remains veiled in secrecy, adding a layer of enigma to the proceedings.

Haleon To Sell ChapStick Lip Balm For $510M : ChapStick Not the Core Focus

Brian McNamara, Haleon’s visionary chief executive, conveyed in a statement that the decision to part ways with the ChapStick brand was rooted in its non-core status within the company. McNamara emphasized that the sale serves as a catalyst to “simplify our business and pay down debt more quickly,” setting the stage for Haleon’s strategic evolution.

EBITDA Ratios and Financial Revitalization

The statement from Haleon revealed aspirations to enhance its EBITDA ratio in 2024. EBITDA, a crucial financial metric encompassing earnings before interest, taxes, depreciation, and amortization, serves as a compass, indicating the company’s trajectory to settle its debt. This financial enigma adds an element of suspense, leaving industry enthusiasts on the edge of their seats.

Haleon’s Debt Landscape – Unveiling the Figures

As of June, the Haleon group grappled with a net debt totaling £9.5 billion ($12.1 billion), witnessing a marginal decline from the £9.9 billion recorded in December 2022. The impending release of the 2023 financial year results on Feb. 29 promises to unravel further details surrounding this strategic transaction.

Haleon To Sell ChapStick Lip Balm For $510M : A Journey Through Time

ChapStick, a pioneer in lip care since the early 1880s, reported a revenue surge of £112 million in the twelve months leading up to the close of 2023. This legacy brand, now poised for a transformative shift under Suave, stands as a testament to enduring success in the ever-evolving beauty industry.

Suave Brands Co.’s Genesis and Suave’s Affordable Quality

Yellow Wood Partners birthed Suave Brands Co. in May 2023, cementing its commitment to the Suave name through the acquisition from Unilever. The private equity firm, harking back to the 1930s, positions Suave as a pioneer in democratizing quality hair care, adding an intriguing historical perspective to the Suave brand.

Haleon’s Stock Ticker Dance

Haleon’s shares, prominently featured on the FTSE 100 index of the London Stock Exchange, remained relatively stable at 314.25 pence early Thursday afternoon, a mere breath away from Wednesday’s close at 313.35 pence. This stock ticker dance encapsulates the market’s response to Haleon’s daring strategic move.

GSK’s Divestment Dance – A Prelude to Haleon’s Evolution

Founded in 2019 through the merger of consumer healthcare giants GSK PLC and Pfizer Inc., Haleon continues to make waves. GSK, formerly GlaxoSmithKline, recently announced a staggering £978 million influx through another share sale in its erstwhile subsidiary Haleon, setting the stage for both companies’ independent trajectories.